What is a tumor board and should my Mantle Cell Lymphoma case be reviewed by one

Understanding Tumor Boards and Your Mantle Cell Lymphoma Care

What Is a Tumor Board?

A tumor board (also called a multidisciplinary tumor conference or case conference) is a meeting where a team of cancer specialists from different fields reviews individual patient cases together. Think of it as a "second opinion by committee" — rather than one doctor making decisions alone, multiple experts collaborate to discuss your diagnosis, test results, and treatment options.

Who typically participates:

• Medical oncologists (cancer drug specialists)
• Hematologists (blood cancer specialists)
• Pathologists (doctors who examine tissue samples)
• Radiologists (imaging specialists)
• Radiation oncologists (radiation therapy specialists)
• Surgeons (when relevant)
• Nurses and other care team members

What they do:

• Review your pathology report and imaging studies
• Discuss your specific disease characteristics (like TP53 mutation status, Ki-67 proliferation fraction, and SOX11 expression)
• Recommend personalized treatment approaches
• Identify clinical trials you might be eligible for
• Ensure nothing important is missed

---

Should Your Mantle Cell Lymphoma Case Be Reviewed?

Yes — tumor board review is particularly valuable for mantle cell lymphoma (MCL).

Here's why:

MCL Requires Complex Decision-Making

According to the NCCN Guidelines for Mantle Cell Lymphoma, your treatment depends on several important factors:

• Disease stage (Stage I/II vs. Stage III/IV)
• TP53 mutation status — This is critical. The NCCN Guidelines note that "TP53 mutation has been associated with poor prognosis in patients treated with conventional therapy, including transplant," and patients with TP53-mutated MCL may need different approaches than those with wild-type TP53
• Ki-67 proliferation fraction (how fast the cancer cells are dividing)
• SOX11 expression — helps determine if your MCL is "classical" or "indolent" (slower-growing)
• Whether you're suitable for aggressive therapy or need a gentler approach
• Your age and overall health

Treatment Options Are Expanding

The NCCN Guidelines outline multiple treatment pathways:

• Aggressive induction therapy (like TRIANGLE regimen with alternating RCHOP + ibrutinib/RDHAP)
• Less aggressive therapy (like bendamustine + rituximab or acalabrutinib-based regimens)
• BTK inhibitors (Bruton tyrosine kinase inhibitors like ibrutinib, acalabrutinib, or zanubrutinib)
• Stem cell transplant (HDT/ASCR) for eligible patients
• CAR T-cell therapy for relapsed/refractory disease
• Clinical trials — often strongly recommended, especially for TP53-mutated cases

A tumor board helps ensure you're matched with the right approach for YOUR specific situation.

---

How to Request a Tumor Board Review

Ask your oncologist directly: "I'd like my case to be reviewed by your tumor board. Can you submit it for discussion?"

Most major cancer centers have formal tumor board processes. Your doctor can:

• Submit your case for review
• Present your situation to the team
• Bring back recommendations to discuss with you

If your current center doesn't have a tumor board, consider:

• Asking for a referral to a comprehensive cancer center (like those affiliated with NCCN)
• Seeking a second opinion from an MCL specialist
• Exploring whether you qualify for clinical trials through resources like ClinicalTrials.gov

---

Questions to Ask Your Oncologist

1. "Will my case be reviewed by a tumor board? If not, why not?"
2. "What are the specific characteristics of my MCL that will influence treatment decisions?" (Ask specifically about TP53 status, Ki-67, SOX11, and stage)
3. "What treatment options does the tumor board recommend for my specific situation?"
4. "Are there clinical trials I should consider?" (The NCCN Guidelines note that clinical trials are "strongly recommended" for certain MCL presentations)
5. "How will we monitor my response to treatment?" (The NCCN Guidelines recommend using Lugano Response Criteria with PET/CT scans)

---

Why This Matters for MCL Specifically

Mantle cell lymphoma is a complex disease where one-size-fits-all treatment doesn't work. According to NCCN Guidelines, patients with indolent MCL (SOX11-negative, IGHV-mutated) may do well with active surveillance, while those with classical MCL typically need more aggressive treatment. A tumor board ensures your team has considered all these nuances before recommending your treatment plan.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.